

ASX RELEASE

17 November 2017

NOVOGEN BECOMES KAZIA THERAPEUTICS

Sydney, 17 November 2017 – Following the Company's Annual General Meeting held on Wednesday 15 November, where shareholders voted to approve all resolutions, the Company is pleased to advise that the name **Kazia Therapeutics Limited** has been formally adopted after registration by ASIC. The ASX has been informed and the Company will trade under the new ticker of KZA from Tuesday 21 November 2017. The Company will also trade under the NASDAQ ticker of KZIA.

CEO Dr James Garner said: "Our new brand, **Kazia Therapeutics**, reflects the innovative, focused and agile company that we have become. I am delighted that shareholders voted in support of our new name and future."

About Kazia Therapeutics Limited

Kazia Therapeutics Limited, formerly Novogen Limited (ASX: KZA, NASDAQ: KZIA) is an agile oncology-focused biotechnology company, based in Sydney, Australia. We have two clinical staged drug development candidates and an early stage discovery program, across a range of oncology indications.

Our lead program is GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR pathway, which is being developed to treat glioblastoma multiforme, the primary and most aggressive form of brain cancer. Licensed from Genentech in late 2016, GDC-0084 is anticipated to enter phase II clinical trials in 2017.

TRXE-002-1, or Cantrixil is Kazia's second drug development candidate under development as a treatment for ovarian cancer. The chemotherapeutic is currently undergoing a Phase 1 clinical trial in hospitals across Australia and the United States. Initial data on this trial is expected to be reported early in 2018.

Board of Directors

Mr Iain Ross Chairman, Non-Executive Director

Mr Bryce Carmine Non-Executive Director

Mr Steven Coffey Non-Executive Director

Dr James Garner Chief Executive Officer, Managing Director